Compugen Ltd.
CGENHealthcare|Biotechnology|IL
$1.96
+0.04 (+2.08%)
Tangible Book / Share
$0.94
Graham Number
$2.80
Cash / Share
$1.32
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06888921 A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer | Ovarian Cancer, Ovarian Cancer Recurrent | P1P2 | Active | 60 | RCT, Double-blind | COM701, Normal Saline |
| NCT06759649 A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies | Neoplasm, Cancer, Malignant Tumors | P1 | Recruiting | 200 | Open-label | COM503, Zimberelimab |
| NCT04570839 COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Endometrial Neoplasms, Ovarian Cancer | P1P2 | Completed | 48 | Open-label | COM701 in combination with BMS-986207 and nivolumab. |
| NCT03667716 COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | Advanced Cancer, Ovarian Cancer | P1 | Completed | 121 | Open-label | COM701, COM701 with Opdivo (Nivolumab). |
| NCT04354246 COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | Advanced Cancer, Ovarian Cancer | P1 | Completed | 94 | Open-label | Dose escalation: COM902 monotherapy., Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE). |